-+ 0.00%
-+ 0.00%
-+ 0.00%

Valneva's IXCHIQ Shows 95% Antibody Seroresponse Sustained Four Years After Single Dose In Adults Aged 18 To 65+

Benzinga·09/30/2025 05:25:37
Listen to the news
  • Long-lasting antibody persistence was comparable in older (65+) and younger adults
    Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya